GLP-1 and Hypoglycemia
Early Phase 1
Active, not recruiting
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Glucagon-Like Peptide- 1 (GLP-1) infusion
- Registration Number
- NCT01858896
- Lead Sponsor
- University of Maryland, Baltimore
- Brief Summary
Low blood sugar can negatively affect how blood vessels function, and this can lead to an increase in the risk for heart attacks, strokes and other problems related to the stiffening and blockage of blood vessels. The purpose of this study is to learn if and how glucagon-like peptide-1 (GLP-1; a naturally occurring hormone in the gut) changes the effects that low blood sugar levels have on blood vessels.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
- 14 (7 males, 7 females) healthy controls age 30-60 yr.
- 14 (7 males, 7 females) people with type 2 DM age 30-60 yr.
- For type 2 DM: HbA1c 6-10.0%
- No significant diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc.)
- Body mass index >25kg • m-2
Exclusion Criteria
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Glucagon-Like Peptide -1 (GLP-1) infusion Glucagon-Like Peptide- 1 (GLP-1) infusion Infusion of GLP-1 during experimental period
- Primary Outcome Measures
Name Time Method Change in Plasminogen Activation inhibitor-1 (PAi-1) change from baseline to end of clamp period measurements of change in PAi-1 at baseline and during the end of the glucose clamp period (2 hours)
Change in Flow mediated dilation (FMD) change from baseline and end of clamp flow mediated dilation of the brachial artery will be measured for change from baseline and end of glucose clamp (\~4 hours)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Maryland, Baltimore
🇺🇸Baltimore, Maryland, United States